Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

The study revealed the following findings: 36.3% of psoriasis patients had elevated high-sensitivity C-reactive protein ...

A new clinical review explores the complexities of treating psoriasis during pregnancy and lactation highlighting limited ...

Innovent Biologics doses first participant in phase 3 clinical study of picankibart: San Francisco Friday, May 30, 2025, 12:00 Hrs [IST] Innovent Biologics, Inc, a world-class bio ...

Most patients with psoriasis experienced clinical improvement or remission after metabolic and bariatric surgery (MBS) in a ...

At least twice as many patients on the approved spesolimab dose maintain improvement in skin symptoms and quality of life ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers ...

Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...

The study reveals that patients with both T2D and psoriasis face a significantly elevated risk of developing renal conditions ...

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...